Flupirtine and retigabine as templates for ligand-based drug design of K<sub>V</sub>7.2/3 activators
作者:Abdrrahman S. Surur、Christian Bock、Kristin Beirow、Konrad Wurm、Lukas Schulig、Markus K. Kindermann、Werner Siegmund、Patrick J. Bednarski、Andreas Link
DOI:10.1039/c9ob00511k
日期:——
of the closely related drugs flupirtine and retigabine, respectively. Experience gained with these drugs strongly suggests that heterotetramer, voltage-gated potassium channels 2 and 3 (KV7.2/3) are valid targets for effective treatment of pain and epilepsy. Because the adverse effects are not related to the mechanism of action, it appears promising to investigate chemical modifications of these clinically
药物性肝损伤(DILI)和组织变色分别导致密切相关的药物氟吡汀和瑞替加滨的治疗最近中断。这些药物获得的经验强烈表明,异四聚体,电压门控钾通道2和3(K V 7.2 / 3)是有效治疗疼痛和癫痫的有效靶点。由于不良反应与作用机理无关,因此研究这些经过临床验证的药物样前导物的化学修饰似乎很有希望。在目前的逆代谢药物设计研究中,合成了一系列43种化合物,并针对K V 7.2 / 3的打开活性和功效进行了表征。活性最高的化合物22d作为K V 7.2 / 3开瓶器,具有出色的效力(EC 50 = 4 nM)和功效(154%)。在高于63μM的浓度下,有限的水溶性阻碍了毒性测试,但是该浓度对培养中的两种肝细胞系(HEP-G2和TAMH)无毒。活性稍差但更易溶的化合物25b(EC 50 = 11 nM,功效111%)与氟吡汀相比,毒性/活性比提高了三个数量级,并代表了引人注目的铅结构,可用于开发更安全的镇痛药和抗癫痫药。